Clinical Efficacy of Didangtang Combined with Gemcitabine in Postoperative Patients with Non-muscle-invasive Bladder Cancer

Yang SHEN; Ming YANG; Qian LU; He-song YE; Lin YUAN

doi:10.13422/j.cnki.syfjx.20210890

您当前的位置：

首页 >

文章列表页 >

Clinical Efficacy of Didangtang Combined with Gemcitabine in Postoperative Patients with Non-muscle-invasive Bladder Cancer

Clinic | 更新时间：2021-03-29

- Clinical Efficacy of Didangtang Combined with Gemcitabine in Postoperative Patients with Non-muscle-invasive Bladder Cancer
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 27, Issue 8, Pages: 94-100(2021)
- 作者机构：
  
  1.南京中医药大学第二附属医院，江苏省第二中医院，南京 210017
  2.南京中医药大学附属医院，江苏省中医院，南京 210000
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20210890
  CLC： R22;R242;R2-031;R287
- Received：17 December 2020，
  
  Published Online：18 February 2021，
  
  Published：20 April 2021
- 稿件说明：
移动端阅览
沈炀,杨明,芦倩等.抵当汤联合吉西他滨治疗非肌层浸润性膀胱癌术后患者的疗效评价[J].中国实验方剂学杂志,2021,27(08):94-100.

SHEN Yang,YANG Ming,LU Qian,et al.Clinical Efficacy of Didangtang Combined with Gemcitabine in Postoperative Patients with Non-muscle-invasive Bladder Cancer[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(08):94-100.
沈炀,杨明,芦倩等.抵当汤联合吉西他滨治疗非肌层浸润性膀胱癌术后患者的疗效评价[J].中国实验方剂学杂志,2021,27(08):94-100. DOI： 10.13422/j.cnki.syfjx.20210890.

SHEN Yang,YANG Ming,LU Qian,et al.Clinical Efficacy of Didangtang Combined with Gemcitabine in Postoperative Patients with Non-muscle-invasive Bladder Cancer[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(08):94-100. DOI： 10.13422/j.cnki.syfjx.20210890.

摘要

目的

观察抵当汤联合吉西他滨膀胱灌注化疗治疗非肌层浸润性膀胱癌术后患者的临床疗效。

方法

选择2015年1月至2019年9月期间于江苏省第二中医院、江苏省中医院就诊的非肌层浸润性膀胱癌患者100例随机分为观察组和对照组，其中观察组50例给予抵当汤联合吉西他滨膀胱灌注治疗，对照组50例给予安慰剂联合吉西他滨膀胱灌注治疗。在治疗周期前后，检测两组患者的血生化、免疫T细胞亚群（CD3

，CD4

，CD8

及CD4

/CD8

）评估治疗组安全性及免疫功能变化；采用膀胱癌患者生命质量核心量表（EORTC QLQ-C30）与浅表性膀胱癌患者特异性量表（EORTC QLQ-BLS24）量化反映治疗前后患者的躯体、角色、情绪与社会等功能情况，疲劳、疼痛、恶心呕吐、气促、失眠、食欲减弱、腹泻和便秘等症状情况及治疗产生问题、未来担心、肠道症状及尿路症状等膀胱癌特异症状。

结果

两组患者年龄、性别、病程和肿瘤分期等均无差异。在治疗周期内，两组均无复发病例及不良反应事件，且观察组中医疗效较对照组明显升高（

= 7.23，

= 0.02）。相较对照组治疗后，观察组中的CD3

，CD4

细胞数量以及CD4

/CD8

都有明显升高（

0.05）。与治疗前相比，两组在角色功能、社会功能和总体健康领域均较治疗前明显升高（

0.05）。此外，观察组的治疗后疲劳、腹泻、便秘、肠道症状以及尿路症状较对照组明显降低（

0.05）。

结论

抵当汤可减轻非肌层浸润性膀胱癌患者术后吉西他滨灌注化疗期间的不良临床症状，改善尿道、肠道不适反应，改善免疫功能，提高患者的生活质量。

Abstract

Objective

To observe the clinical efficacy of Didangtang combined with gemcitabine chemotherapy in postoperative patients with non-muscle invasive bladder ctraditional chinese medicineancer （NMIBC）.

Method

A total of 100 patients with NMIBC in Jiangsu Provincial Second Chinese Medicine Hospital and Jiangsu Province Hospital of Chinese Medicine from January 2015 to September 2020 were randomly divided into control group and treatment group. 50 cases in the treatment group received Didangtang combined with intravesical infusion of gemcitabine， and 50 cases in the control group received placebo combined with intravesical infusion of gemcitabine. Before and after the treatment cycle， the blood biochemistry， immune cell subsets（CD3

，CD4

and CD4

/CD8

） were detected to assess the safety and immune function changes in treatment group. Quality of life scale for patients with bladder cancer prepared by European Organization for the Research and Treatment of Cancer （EORTC QLQ-C30） and Specificity scale for patients with superficial bladder cancer （EORTC QLQ-BLS24） were scored to assess the changes in physical， role， emotional and social functioning of the patients， symptomatic conditions such as fatigue， pain， nausea and vomiting， shortness of breath， insomnia， loss of appetite， diarrhea and constipation， as well as bladder cancer-specific symptoms such as treatment-generated problems， future concerns， bowel symptoms and urinary tract symptoms.

Result

There were no differences in terms of age， sex， disease duration and tumor states. During the treatment period， both groups had no recurrence or adverse events. The traditional Chinese medicine（TCM） efficacy in the treatment group was significantly better than that in the control group（

= 7.23，

= 0.02）. After treatment， the number of CD3

，CD4

，CD8

cells and the CD4

/CD8

ratio in the treatment group were significantly higher than those in control group（

0.05）. Both groups showed significant improvements in the domains of role functioning， social functioning， and general health after treatment （

0.05）. In addition， fatigue， diarrhea， constipation， intestinal symptoms， and urinary tract symptoms in the treatment group were significantly better than those in the control group after treatment （

0.05）.

Conclusion

Didangtang can reduce adverse clinical symptoms during postoperative gemcitabine infusion chemotherapy in patients with NMIBC， reduce urethral and intestinal discomfort reactions， improve immune function and enhance quality of life for patients.

关键词

Keywords

references

CHEN W ， ZHENG R ， BAADE P D ， et al . Cancer statistics in China，2015 ［J］. CA Cancer J Clin ， 2016 ， 66 （ 2 ）： 115 - 132 .

中国研究型医院学会泌尿外科学专业委员会，中国医疗保健国际交流促进会泌尿健康促进分会，中国医疗保健国际交流促进会循证医学分会，等 . 中国非肌层浸润性膀胱癌治疗与监测循证临床实践指南（2018年标准版）［J］. 现代泌尿外科杂志， 2019 ， 24 （ 7 ）： 516 - 542 .

GINGRICH J R . Bladder cancer：chemohyperthermia for bladder cancer--clinically effective？［J］. Nat Rev Urol ， 2011 ， 8 （ 8 ）： 414 - 416 .

张英，侯炜，林洪生 . 中医药治疗恶性肿瘤临床研究成果与思考［J］. 中医杂志， 2014 ， 55 （ 6 ）： 523 - 525 .

刘春萍，曾星 . 中医药抗膀胱癌的研究进展［J］. 时珍国医国药， 2016 ， 27 （ 5 ）： 1184 - 1186 .

尹学来，刘海华，高筱松 . 张亚强治疗膀胱癌临床经验［J］. 山东中医药大学学报， 2016 ， 40 （ 3 ）： 253 - 255 .

陈惠，马超英 . 近年来中西结合治疗膀胱癌的研究进展［J］. 中华中医药学刊， 2014 ， 32 （ 4 ）： 740 - 741 .

张恺，鄢祺，阮善明 . 中药联合膀胱灌注治疗非肌层浸润性膀胱癌根治术后Meta分析［J］. 浙江中西医结合杂志， 2020 ， 30 （ 7 ）： 589 - 595 .

王庆才 . 仲景方药与肿瘤临床［J］. 辽宁中医杂志， 2000 ， 27 （ 8 ）： 344 - 346 .

沈炀，芦倩，张东健，等 . 基于网络药理学探讨抵当汤治疗膀胱癌的作用机制［J］. 中国实验方剂学杂志， 2020 ， 26 （ 14 ）： 200 - 207 .

那彦群，叶章群，孙颖浩，等 . 中国泌尿外科疾病诊断治疗指南手册［M］. 北京：人民卫生出版社， 2014 .

郑筱萸 . 中药新药临床研究指导原则（试行）［M］. 北京：中国医药科技出版社， 2002 .

杨运高，华何与，陈先明，等 . 中药抵当汤对小鼠结肠癌脾移植肝转移模型肿瘤增殖细胞核抗原的影响［J］. 中国老年学杂志， 2013 ， 33 （ 3 ）： 579 - 581 .

姜波，艾华 . 抵当汤化裁方对荷瘤小鼠抑瘤作用及对T淋巴细胞亚群的影响［J］. 吉林中医药， 2008 ， 28 （ 2 ）： 147 - 148 .

任庆，熊锐华，田秀荣，等 . 吉西他滨联合顺铂治疗晚期膀胱癌的临床观察［J］. 重庆医学， 2014 ， 43 （ 34 ）： 4660 - 4661 .

蒋远斌，王铀，郭宇，等 . 丹参饮对化疗后气阴两虚型膀胱癌患者胃肠道抑制及免疫功能的影响［J］. 中国实验方剂学杂志， 2017 ， 23 （ 15 ）： 191 - 195 .

杜梦楠，易丹 . 浅述李中梓“治泻九法”在化疗相关性腹泻中的应用［J］. 中医肿瘤学杂志， 2020 ， 2 （ 4 ）： 11 - 14，40 .

杨明，叶和松，秦远，等 . 彭培初自拟方联合吉西他滨治疗非肌层浸润性膀胱癌术后的临床观察［J］. 中成药， 2019 ， 41 （ 5 ）： 1188 - 1190 .

JOZWICKI W ， BROZYNA A A ， SIEKIERA J ， et al . Changes in immunogenicity during the development of urinary bladder cancer： a preliminary study ［J］. Int J Mol Sci ， 2016 ， 17 （ 3 ）： 285 .

姜丰泽，蒋思雄，田丰，等 . 鸦胆子油乳联合常规化疗方案对局部晚期膀胱癌患者的疗效观察及免疫功能的影响［J］. 中华保健医学杂志， 2019 ， 21 （ 1 ）： 24 - 27 .

OH D Y ， KWEK S S ， RAJU S S ， et al . Intratumoral CD4 + T Cells mediate anti-tumor cytotoxicity in human bladder cancer ［J］. Cell ， 2020 ， 181 （ 7 ）： 1612 - 1625 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Efficacy of Chonglian Oral Liquid on COVID-19 Patients

Mechanism of Didangtang in Treatment of Bladder Cancer Based on Network Pharmacology

Clinical Efficacy of Zhuyuwan in Treatment of Hyperlipidemia with Syndrome of Phlegm Turbidity and Obstruction

Clinical Randomized Controlled Trial of Traditional Chinese Medicine Compound Shenlong Decoction Granules in Treatment of Idiopathic Pulmonary Fibrosis

Mechanism of Traditional Chinese Medicine Regulating JAK/STAT Signaling Pathway to Intervene in Lung Cancer： A Review

Related Author

ZHOU Tong

ZHANG Xi'an

TIAN Yuli

CI Huimin

WANG Xinru

ZHU Caiyun

LI Zegeng

TONG Jiabing

Related Institution

Anhui University of Chinese Medicine

First Affiliated Hospital，Anhui University of Chinese Medicine

Key Laboratory of Traditional Chinese Medicine for Prevention and Treatment of Lung Diseases， Key Laboratory of Anhui Provincial Department of Education

Center for Xin'an Medicine and Modernization of Traditional Chinese Medicine， Institute of Health and Medicine，Hefei Comprehensive National Science Center

Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰